Although canakinumab is the only IL-1 inhibitor approved for the treatment of MKD and TRAPS, it did not appear systematically given to MKD and TRAPS patients in real-life practice: 47.5% of MKD patients, and 14.3% of TRAPS patients in the JIR cohort received canakinumab. Here, IL1B is linked to mevalonic aciduria.